Puromycin Aminonucleoside: Precision Nephrotoxic Agent for Podocyte Injury Models

Executive Summary: Puromycin aminonucleoside (A3740, APExBIO) is the aminonucleoside moiety isolated from puromycin, widely deployed as a nephrotoxic agent for preclinical nephrotic syndrome and FSGS models. In vivo, it induces proteinuria and glomerular lesions through podocyte injury, with hallmark reductions in nephrin expression and foot process effacement. The compound exhibits PMAT transporter-mediated uptake, with higher cytotoxicity under acidic conditions in PMAT-expressing MDCK cells. Puromycin aminonucleoside is highly soluble in water, ethanol, and DMSO, and must be stored at -20°C for stability. Its robust, reproducible mechanism supports its status as a gold-standard tool for renal pathophysiology studies (APExBIO A3740).

Biological Rationale

Puromycin aminonucleoside is derived from the aminonucleoside moiety of the antibiotic puromycin (CAS 58-60-6) and is structurally optimized for experimental induction of nephrotic injury. It serves as a benchmark nephrotoxic agent for modeling proteinuria and glomerular lesions characteristic of human nephrotic syndrome and focal segmental glomerulosclerosis (FSGS) (APExBIO). The compound's specificity for podocyte injury enables controlled study of renal function impairment and mechanisms underlying glomerular barrier disruption. By recapitulating podocyte cytoskeletal and morphological alterations, researchers can delineate the cellular events driving proteinuria, a central phenotype in nephrotic syndrome. Use in animal models, particularly rats, supports translational relevance and benchmark comparisons across studies (see mechanistic analysis).

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside alters podocyte morphology in vitro, causing a marked reduction in cellular microvilli and disruption of foot processes—both essential for maintaining glomerular filtration barrier integrity. In vector- and PMAT-transfected Madin-Darby canine kidney (MDCK) cells, the compound exhibits cytotoxicity with IC50 values of 48.9 ± 2.8 μM and 122.1 ± 14.5 μM, respectively, under standard culture conditions. Uptake is potentiated in PMAT-expressing cells, especially at acidic pH (6.6), indicating a transporter-mediated entry mechanism. In vivo, intravenous or subcutaneous administration in rats induces glomerular lesions, proteinuria, and lipid accumulation in mesangial cells, closely modeling FSGS and nephrotic syndrome (see precision agent guide). The compound reduces nephrin expression, a critical podocyte marker, and impairs overall renal function. Puromycin aminonucleoside's nephrotoxic effect is dose- and time-dependent, with observable renal pathology within days of administration (typically 10–15 mg/kg in rats).

Evidence & Benchmarks

• Puromycin aminonucleoside induces severe proteinuria and glomerular lesions in rats, serving as a validated model for focal segmental glomerulosclerosis (FSGS) (APExBIO).
• It causes dose-dependent podocyte injury and loss of foot process structure in vitro and in vivo (AS602801.com, mechanistic insight).
• PMAT transporter expression significantly increases cellular uptake and cytotoxicity of puromycin aminonucleoside under acidic pH conditions (pH 6.6), with IC50 values of 48.9 ± 2.8 μM in vector-transfected and 122.1 ± 14.5 μM in PMAT-transfected MDCK cells (APExBIO).
• Glomerular lesions and proteinuria induced by puromycin aminonucleoside are reproducible and closely resemble human nephrotic syndrome pathology (ABT263.com, standardized workflow).
• Compound is soluble at ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water with gentle warming, supporting diverse experimental protocols (APExBIO).

Applications, Limits & Misconceptions

Puromycin aminonucleoside’s primary applications include:

• Induction of proteinuria and glomerular injury in rodent models for nephrotic syndrome and FSGS research.
• Assessment of podocyte-specific cytoskeletal and functional disruption.
• Pharmacological testing of nephroprotective or regenerative compounds in established proteinuria models.
• In vitro studies on PMAT transporter function and podocyte biology.

For a deeper mechanistic and translational comparison, see this review, which contextualizes puromycin aminonucleoside’s role within evolving renal precision medicine strategies; the current article extends these insights by integrating updated cytotoxicity and solubility data for experimental design optimization.

Common Pitfalls or Misconceptions

• Puromycin aminonucleoside does not induce nephrotic syndrome phenotypes in all rodent strains; genetic and age differences affect susceptibility.
• The compound is not appropriate for chronic kidney disease models unrelated to podocyte injury (e.g., tubulointerstitial nephritis).
• Improper storage or repeated freeze-thaw cycles can degrade compound potency and confound results; always store at -20°C and minimize solution storage time.
• It does not model immune-mediated glomerular diseases; its effects are predominantly direct cytotoxicity on podocytes.
• Cytotoxicity and uptake are highly pH- and transporter-dependent; ignoring these factors can cause erroneous interpretation of in vitro results.

Workflow Integration & Parameters

To maximize reproducibility, dissolve puromycin aminonucleoside at ≥29.5 mg/mL in water (gentle warming), or as needed in DMSO or ethanol for in vitro work. Store powder at -20°C and prepare fresh solutions before use. For in vivo models, typical dosing in rats is 10–15 mg/kg via intravenous or subcutaneous injection. Monitor for proteinuria (urinary albumin excretion), serum creatinine, and histological assessment of glomeruli. In vitro, apply compound to podocyte or PMAT-transfected MDCK cells at defined IC50 concentrations and standardize pH conditions for transporter studies. For troubleshooting and advanced applications, see this workflow guide, which the present article updates with expanded solubility and cytotoxicity benchmarks.

Conclusion & Outlook

Puromycin aminonucleoside (APExBIO A3740) remains the gold-standard nephrotoxic agent for mechanistic and translational nephrotic syndrome research. Its defined podocyte injury mechanism, robust cytotoxicity profile, and compatibility with PMAT transporter studies ensure high experimental reliability. As renal research advances toward precision modeling and biomarker discovery, puromycin aminonucleoside’s reproducibility and mechanistic clarity position it as a critical tool for the next generation of nephrology studies. For ordering or technical details, see the Puromycin aminonucleoside product page.